CHClaes Hansson
Claes Hansson
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Claes Hansson has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Catharina Eriksson
Department of Clinical Microbiology/Clinical Immunology, Umeå University, 901 87 Umeå, Sweden
1 shared publication- Gerd-Marie Alenius
Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, 901 87 Umeå, Sweden
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Wiley in Journal of Immunology Research
- Vol. 2014, 1-5
S-Calprotectin (S100A8/S100A9): A Potential Marker of Inflammation in Patients with Psoriatic Arthritis
Objective. To analyse levels of S100A8/S100A9 (calprotectin) and selected cytokines, in blood, in patients with psoriatic arthritis (PsA).Methods. Sixty-five patients with PsA were examined for clinical manifestations and laboratory measurements of S-calprotectin, ESR, hs-CRP, and selected cytokines. Thirty-two patients had mono-/oligoarthritis and 33 had polyarthritis. S-calprotectin, hs-CRP, and cytokines were measured using ELISA, immunoturbidimetry, and multiplex technology (Bio-Plex). Patients with PsA were compared with 31 healthy controls.Results. S-calprotectin and hs-CRP levels were significantly higher in patients with PsA compared with controls (and, resp.). Patients suffering a polyarthritic disease pattern presented with significantly higher levels of S-calprotectin compared with controls and patients with mono-/oligoarthritis (and, resp.). The levels of S-calprotectin correlated with hs-CRP (;), swollen joint count (,), and CXCL10 (,) but not with any of the other cytokines evaluated. In multiple logistic regression analysis, S-calprotectin was the only variable significantly associated with psoriatic arthritis (,, 95% CI = 1.002–1.010).Conclusion. S-calprotectin and hs-CRP levels were significantly higher in patients with PsA. A polyarthritic disease pattern showed higher levels of S-calprotectin than mono-/oligoarthritis. S-calprotectin is considered a potential marker of disease activity in patients with PsA.- 1 January 2014
- Published by Wiley in Journal of Immunology Research
- Vol. 2014, 1-5
Open AccessS-Calprotectin (S100A8/S100A9): A Potential Marker of Inflammation in Patients with Psoriatic Arthritis
Objective. To analyse levels of S100A8/S100A9 (calprotectin) and selected cytokines, in blood, in patients with psoriatic arthritis (PsA).Methods. Sixty-five patients with PsA were examined for clinical manifestations and laboratory measurements of S-calprotectin, ESR, hs-CRP, and selected cytokines. Thirty-two patients had mono-/oligoarthritis and 33 had polyarthritis. S-calprotectin, hs-CRP, and cytokines were measured using ELISA, immunoturbidimetry, and multiplex technology (Bio-Plex). Patients with PsA were compared with 31 healthy controls.Results. S-calprotectin and hs-CRP levels were significantly higher in patients with PsA compared with controls (and, resp.). Patients suffering a polyarthritic disease pattern presented with significantly higher levels of S-calprotectin compared with controls and patients with mono-/oligoarthritis (and, resp.). The levels of S-calprotectin correlated with hs-CRP (;), swollen joint count (,), and CXCL10 (,) but not with any of the other cytokines evaluated. In multiple logistic regression analysis, S-calprotectin was the only variable significantly associated with psoriatic arthritis (,, 95% CI = 1.002–1.010).Conclusion. S-calprotectin and hs-CRP levels were significantly higher in patients with PsA. A polyarthritic disease pattern showed higher levels of S-calprotectin than mono-/oligoarthritis. S-calprotectin is considered a potential marker of disease activity in patients with PsA.